Aspyra Receives Notice from NYSE Amex LLC
01 October 2009 - 6:35AM
Business Wire
Aspyra, Inc. (AMEX: APY), a provider of clinical and
diagnostic information systems for the healthcare industry, today
reported it has received notice from NYSE Amex LLC (the “Exchange”)
that the Company does not meet one of the Exchange’s continued
listing standards as set forth in Part 10 of the NYSE Amex LLC
Company Guide (the “Company Guide”).
The notice reports that Aspyra is not in compliance with Section
1003(a)(iv) of the Company Guide. The Company was afforded the
opportunity to submit a plan of compliance to the Exchange by
October 26, 2009, addressing how it intends to regain compliance
with Section 1003(a)(iv) of the Company Guide by March 24,
2010.
Rodney Schutt, CEO for Aspyra, stated, “Based on the economic
climate and similar compliance issues facing companies throughout
the healthcare industry, we are aware of the regulatory compliance
requirements, and for several months have been evaluating the cost
versus benefit of remaining a publicly traded and reporting
company.”
Aspyra is a global provider of Health Care Information
Technology (HCIT) solutions and services to the healthcare
industry. The Company specializes in Clinical Information Systems
(CIS), Picture Archive Communication Systems (PACS) for hospitals,
multi-specialty clinics, clinical laboratories, imaging departments
and centers and orthopedic environments. Aspyra's highly scalable
systems can be installed standalone or integrated to provide a
single-vendor, enterprise-wide solution. For more information on
Aspyra, visit www.aspyra.com.
Safe Harbor
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to anticipated revenues,
expenses, earnings, operating cash flows, the outlook for Aspyra’s
markets and the demand for its products. Forward-looking statements
are not guarantees of future performance and are inherently subject
to uncertainties and other factors which could cause actual results
to differ materially from the forward-looking statement. Such
statements are based upon, among other things, assumptions made by,
and information currently available to, management as of today the
date of this press release, including management's own knowledge
and assessment of the Company’s industry and competition. Factors
that could cause Aspyra’s actual results to differ materially from
these forward-looking statements include among others: the
competitive environment; unexpected technical and marketing
difficulties inherent in major product development efforts; the
potential need for changes in our long-term strategy in response to
future developments; future advances in clinical information
technology and procedures, as well as potential changes in
government regulations and healthcare policies; and rapid
technological change in the microelectronics and software
industries. The Company refers interested persons to its most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and its other SEC filings for a description of additional
uncertainties and factors, which may affect forward-looking
statements. The Company assumes no duty to update its
forward-looking statements.
Aspyra (AMEX:APY)
Historical Stock Chart
From Nov 2024 to Dec 2024
Aspyra (AMEX:APY)
Historical Stock Chart
From Dec 2023 to Dec 2024